RxDoctor Payments Data

Puneet Gupta, MD

Interventional Cardiology · Canton, OHNPI 1427498674

Payments from drug & device makers

$2,204in general payments, 2019–2025

Across 108 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$409
  • Abbott$304
  • Johnson & Johnson$268
  • Amgen$184
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$182
  • Terumo Medical Corporation$119
  • plus $738 from 19 others

What the payments were for

  • Food & beverage$2,00991%
  • Education$1959%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,204 in reported general payments places this provider in the 30th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$170,795
Medicare patients
877
Services billed
2,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan133$150,504
EliquisApixaban119$128,058
XareltoRivaroxaban67$65,023
BrilintaTicagrelor17$16,883
Repatha SureclickEvolocumab20$15,229
VascepaIcosapent Ethyl34$12,250
Ranolazine ErRanolazine103$7,679
Prasugrel Hcl36$5,227
Metoprolol Succinate301$2,880
Atorvastatin Calcium300$2,178
Amiodarone Hcl49$1,996
Isosorbide Mononitrate ErIsosorbide Mononitrate254$1,961
Rosuvastatin Calcium95$1,541
Omega-3 Acid Ethyl Esters34$1,469
ClopidogrelClopidogrel Bisulfate136$1,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$409$150,504133 claims
PfizerEliquis$95$128,058119 claims
Johnson & JohnsonXarelto$268$65,02367 claims
AstraZenecaBrilinta$58$16,88317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Canton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →